Identification of Significant Mutations in Spike Protein of SARS‐CoV‐2 Variants of Concern and the Discovery of Potent Inhibitors
Authors:
- Mohsen AlmakramiMAMohsen Almakrami
- Mohammed BazuqamahMohammed Bazuqamah
- Mohammed A. AlshehriMAMohammed A. Alshehri
- Abdulaziz M. S. AlqahtaniAAAbdulaziz M. S. Alqahtani
- Sultan F. KadasahSKSultan F. Kadasah
- Naif HarthiNHNaif Harthi
- Abdulmajeed AlqurashiAAAbdulmajeed Alqurashi
- Abdulhadi A. Al RuwaithiARAbdulhadi A. Al Ruwaithi
Open Access
- 1 January 2025
- journal article
- Published by Wiley in Global Health, Epidemiology and Genomics
- Vol. 2025 (1) , 5042190
Abstract
Background: SARS‐CoV‐2 is a positive‐sense single‐stranded RNA virus that has a propensity for infecting epithelial cells and the respiratory system. The two important proteins, structural and nonstructural proteins, make the architecture of this virus. Aim: This research aimed at studying significant mutations in spike protein of SARS‐CoV‐2 variants of concern (VoCs) and finding shared mutations among omicron and other four variants (alpha, beta, gamma, and delta). The purpose of this study was to draw structural comparisons between wild type and mutant proteins, followed by identifying potent inhibitors (ligand) that could be used against SARS‐CoV‐2 spike protein and its latest omicron VoC. Methodology: In this research, we had studied 16 major mutations as well as shared mutations (6) present in spike region of SARS‐CoV‐2. Subsequently, we determined the structure of the wild‐type SARS‐CoV‐2 protein from the Protein Data Bank (PDB) with the ID 7R4I. Furthermore, the structure of the mutant protein of SARS‐CoV‐2 omicron variant was modeled in SWISS‐MODEL. The ligand dataset for spike protein of SARS‐CoV‐2 was also collected from literature and different databases. Both wild type and mutant proteins were docked with ligand database in Molecular Operating Environment (MOE). The docking analysis was performed, and two best ligand molecules, AZ_2 and AZ_13, were finalized based on their energy values, interactions, and docking scores to be used against our wild and mutant proteins. Results: AZ_2 demonstrated a docking score of −6.1753 in MOE, with energy values of −4.3889 and −6.1753. It formed key hydrogen bond interactions. AZ_13 showed a docking score of −5.9, with energy values of −9.3 and −5.9, forming hydrogen donor and acceptor interactions with Asp950 (3.06 Å), Ile312 (3.13 Å), and Glu309 (3.27 Å). These interactions suggest strong binding affinity and potential efficacy. Thus, present research work emphasized on identification of significant mutations and finding a potent target‐based drug against SARS‐CoV‐2 and its omicron variant. Outcomes: Based on this computational analysis performed, it is suggested that proposed compound can be used as remedy against SARS‐CoV‐2 and its omicron variant.Keywords
This publication has 40 references indexed in Scilit:
- Design, molecular docking and MD simulation of novel estradiol-pyrimidine analogues as potential inhibitors of Mpro and ACE2 for COVID-19Chemical Physics Impact, 2024
- The ins and outs of SARS-CoV-2 variants of concern (VOCs)Archives of Virology, 2022
- Severe Acute Respiratory Syndrome Type 2‐Causing Coronavirus: Variants and Preventive StrategiesAdvanced Science, 2022
- Evolution of the SARS-CoV-2 genome and emergence of variants of concernArchives of Virology, 2021
- Emerging mutations in the SARS-CoV-2 variants and their role in antibody escape to small molecule-based therapeutic resistanceCurrent Opinion in Pharmacology, 2021
- Structural Proteins in Severe Acute Respiratory Syndrome Coronavirus-2Archives of Medical Research, 2020
- The Natural History, Pathobiology, and Clinical Manifestations of SARS-CoV-2 InfectionsJournal of Neuroimmune Pharmacology, 2020
- Curcumin: a Wonder Drug as a Preventive Measure for COVID19 ManagementIndian Journal of Clinical Biochemistry, 2020
- COVID-19 pathophysiology: A reviewClinical Immunology, 2020
- Automated comparative protein structure modeling with SWISS‐MODEL and Swiss‐PdbViewer: A historical perspectiveElectrophoresis, 2009